文献速递泌尿男性生殖肿瘤

透明质酸直肠间隔物用于大分割前列腺放疗:一项随机临床试验

Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: A Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2023-01-01

这项多中心随机临床试验纳入201例T1-T2、Gleason≤7、PSA≤20 ng/mL的前列腺癌患者,按2:1随机分为透明质酸直肠间隔物组和无间隔物对照组,评估大分割放疗的直肠剂量学和急性胃肠道毒性。结果显示间隔物组98.5%患者直肠V54降低≥25%,急性≥2级胃肠道毒性间隔物组2.9% vs 对照组13.8%。

要点

  • 间隔物组98.5%患者达到直肠V54降低≥25%,超过预设的70%阈值(P<.001)。
  • 急性≥2级胃肠道毒性间隔物组2.9% vs 对照组13.8%,差异-10.9%(P=.01)。
  • 作者认为直肠间隔物可考虑用于降低大分割放疗急性≥2级毒性风险。

核心结论

  • 试验结果提示透明质酸直肠间隔物改善直肠剂量学并降低急性≥2级胃肠道毒性。
  • 作者认为可考虑使用直肠间隔物以降低大分割放疗急性≥2级毒性风险。

研究设计与样本

  • 随机临床试验,2020年3月至2021年6月在美国、澳大利亚和西班牙的12个中心开展,随访6个月。
  • 纳入活检证实、T1-T2、Gleason评分≤7且前列腺特异性抗原≤20 ng/mL的成年前列腺癌患者,患者对治疗分组设盲。
  • 260例同意患者中201例(77.3%)按2:1随机分配至使用或不使用间隔物,按计划4个月雄激素剥夺治疗使用和勃起质量分层。

主要发现

  • 间隔物组133例中131例(98.5%;95%CI 94.7%-99.8%)直肠V54降低≥25%,高于最低可接受值70%(P<.001),平均(SD)降低85.0%(20.9%)。
  • 急性≥2级胃肠道毒性间隔物组136例中4例(2.9%)vs 对照组65例中9例(13.8%),差异-10.9%(95%单侧置信上限-3.5;P=.01)。
  • 201例随机患者中亚洲8例(4.0%)、黑人26例(12.9%)、西班牙裔或拉丁裔42例(20.9%)、白人153例(76.1%);间隔物组平均(SD)年龄68.6(7.2)岁,对照组68.4(7.3)岁。

关键数值与推荐

  • 主要结局假设间隔物组超过70%患者直肠V54降低≥25%。
  • 次要结局假设间隔物组急性(3个月内)≥2级胃肠道毒性与对照组非劣效,界值10%。

临床怎么用

  • 作者认为可考虑使用直肠间隔物以降低大分割放疗急性≥2级毒性风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hypofractionated radiation therapy (RT) for prostate cancer has been associated with greater acute grade 2 gastrointestinal (GI) toxic effects compared with conventionally fractionated RT. OBJECTIVE: To evaluate whether a hyaluronic acid rectal spacer could (1) improve rectal dosimetry and (2) affect acute grade 2 or higher GI toxic effects for hypofractionated RT. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted from March 2020 to June 2021 among 12 centers within the US, Australia, and Spain, with a 6-month follow-up. Adult patients with biopsy-proven, T1 to T2 prostate cancer with a Gleason score 7 or less and prostate-specific antigen level of 20 ng/mL or less (to convert to μg/L, multiply by 1) were blinded to the treatment arms. Of the 260 consented patients, 201 patients (77.3%) were randomized (2:1) to the presence or absence of the spacer. Patients were stratified by intended 4-month androgen deprivation therapy use and erectile quality. MAIN OUTCOMES AND MEASURES: For the primary outcome, we hypothesized that more than 70% of patients in the spacer group would achieve a 25% or greater reduction in the rectal volume receiving 54 Gy (V54). For the secondary outcome, we hypothesized that the spacer group would have noninferior acute (within 3 months) grade 2 or higher GI toxic effects compared with the control group, with a margin of 10%. RESULTS: Of the 201 randomized patients, 8 (4.0%) were Asian, 26 (12.9%) Black, 42 (20.9%) Hispanic or Latino, and 153 (76.1%) White; the mean (SD) age for the spacer group was 68.6 (7.2) years and 68.4 (7.3) years for the control group. For the primary outcome, 131 of 133 (98.5%; 95% CI, 94.7%-99.8%) patients in the spacer group experienced a 25% or greater reduction in rectum V54, which was greater than the minimally acceptable 70% (P < .001). The mean (SD) reduction was 85.0% (20.9%). For the secondary outcome, 4 of 136 patients (2.9%) in the spacer group and 9 of 65 patients (13.8%) in the control group experienced acute grade 2 or higher GI toxic effects (difference, -10.9%; 95% 1-sided upper confidence limit, -3.5; P = .01). CONCLUSIONS AND RELEVANCE: The trial results suggest that rectal spacing with hyaluronic acid improved rectal dosimetry and reduced acute grade 2 or higher GI toxic effects. Rectal spacing should potentially be considered for minimizing the risk of acute grade 2 or higher toxic effects for hypofractionated RT. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04189913.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Mariados NF, Orio PF, Schiffman Z, et al. Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: A Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 36757690. doi:10.1001/jamaoncol.2022.7592

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。